Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Alumis Logo
Alumis Growth Score
45
CB Rank
6277
Heat Score
33
Alumis is a precision medicine company focused on the discovery, development and treatment of autoimmune disorders.
Founded
obfuscation
PublicPost-IPO Equity San Francisco, California, United States101-250 www.alumis.com
Biotechnology
Health Care
Life Science
Medical
Precision Medicine
Overview

Alumis
Total Funding
obfuscation
Growth Score
45
Heat Score
33

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score45
-20 pts
in past quarter
Heat Score 33
-10 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Alumis

CB Rank
6277
Alumis is a precision medicine company focused on the discovery, development and treatment of autoimmune disorders.
Founded
obfuscation
PublicPost-IPO Equity San Francisco, California, United States101-250 www.alumis.com
Biotechnology
Health Care
Life Science
Medical
Precision Medicine

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Secondary
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation

Key People

Details

Legal Name Alumis Inc.
Also Known As Esker Therapeutics
Operating Status Active
Stock Symbol  NASDAQ:ALMS
Company Type For Profit
Founders  June Lee
About the Company
Alumis develops precision medications to treat autoimmune illnesses. The company's analytics platform and understanding of immunologic disorders aid in the development of treatments and medications for autoimmune diseases, allowing patients to alleviate suffering and modify their way of life.
Phone Number +1- 650-231-6625
Contact Email hello@eskertx.com
Diversity Spotlight 
Women Founded
Predictions & Insights

Growth Insight

See this Growth Insight
Alumis is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Growth Prediction

See this Growth Prediction

Products & Services

ESK-001
An oral TYK2 inhibitor in clinical development for moderate to severe plaque psoriasis and systemic lupus erythematosus (SLE).
ESK-001
An oral TYK2 inhibitor in clinical development for treating moderate to severe plaque psoriasis and systemic lupus erythematosus (SLE).

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 7
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Alumis Logo
Post-IPO Equity - Alumis
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Alumis Logo
Post-IPO Equity - Alumis
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Alumis Logo
Post-IPO Equity - Alumis
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Alumis Logo
Post-IPO Equity - Alumis
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Alumis Logo
Post-IPO Equity - Alumis
—
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 7
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Alumis Logo
Post-IPO Equity - Alumis
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Alumis Logo
Post-IPO Equity - Alumis
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Alumis Logo
Post-IPO Equity - Alumis
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Alumis Logo
Post-IPO Equity - Alumis
—
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Alumis Logo
Post-IPO Equity - Alumis
—
obfuscation
— Post-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
Foresite Capital Logo
Foresite Capital
Yes
Post-IPO Secondary - Alumis Logo
Post-IPO Secondary - Alumis
—
Foresite Capital Logo
Foresite Capital
Yes
Post-IPO Secondary - Alumis Logo
Post-IPO Secondary - Alumis
—
Foresite Capital Logo
Foresite Capital
Yes
Post-IPO Secondary - Alumis Logo
Post-IPO Secondary - Alumis
—
Foresite Capital Logo
Foresite Capital
Yes
Post-IPO Secondary - Alumis Logo
Post-IPO Secondary - Alumis
—
Foresite Capital Logo
Foresite Capital
Yes
Post-IPO Secondary - Alumis Logo
Post-IPO Secondary - Alumis
—

Investments

Number of Acquisitions 1

Investment Breakdown

Number of Acquisitions 1
Market Intelligence
People
View Profiles & Contacts
Headcount 101-250 Employee Profiles 6 Board Members and Advisors 4 Contacts 72

Employee Profiles

Board Members and Advisors

News

News and Press

News•Jun 5, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 17, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 15, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 14, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

3,397
-49.28%
 in past month

IT Spend

$1.3MThis year, Alumis is projected to spend $1.3M on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
Qlik Sense Logo
Qlik Sense
100
TechCrunch Disrupt Logo
TechCrunch Disrupt
99
The Wall Street Journal Logo
The Wall Street Journal
97

Active Website Tech Count

8Alumis is actively using 8 technologies for its website, according to BuiltWith. These include SSL by Default, U.S. Server Location, and  CommonCrawl Top 5m.
Sub-Organizations
Frequently Asked Questions

Where is Alumis's headquarters? Alumis is located in San Francisco, California, United States.Who invested in Alumis? Alumis has 13 investors including Foresite Capital and  Samsara BioCapital.When was the last funding round for Alumis? Alumis closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are Alumis's competitors? Alternatives and possible competitors to Alumis may include BioAge Labs, Avalyn Pharma, and  Q32 Bio.How much funding has Alumis raised to date? Alumis has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(05b78c5 1)
|